[go: up one dir, main page]

MX2019010804A - Compuestos de benzazepina, conjugados y usos de los mismos. - Google Patents

Compuestos de benzazepina, conjugados y usos de los mismos.

Info

Publication number
MX2019010804A
MX2019010804A MX2019010804A MX2019010804A MX2019010804A MX 2019010804 A MX2019010804 A MX 2019010804A MX 2019010804 A MX2019010804 A MX 2019010804A MX 2019010804 A MX2019010804 A MX 2019010804A MX 2019010804 A MX2019010804 A MX 2019010804A
Authority
MX
Mexico
Prior art keywords
benzazepine compounds
conjugates
cancer
benzazepine
disclosed
Prior art date
Application number
MX2019010804A
Other languages
English (en)
Inventor
Robert Baum Peter
Alan Coburn Craig
Wesley Smith Sean
Original Assignee
Silverback Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Silverback Therapeutics Inc filed Critical Silverback Therapeutics Inc
Publication of MX2019010804A publication Critical patent/MX2019010804A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

En la presente se describen compuestos de benzazepina, conjugados y composiciones farmacéuticas para uso en el tratamiento de enfermedades como por ejemplo cáncer. Los compuestos de benzazepina descritos son útiles, entre otras cosas, para el tratamiento de cáncer y modulación de TLR8. Adicionalmente, los compuestos de benzazepina incorporados en un conjugado con una construcción de anticuerpo se describe en la presente.
MX2019010804A 2017-03-15 2018-03-14 Compuestos de benzazepina, conjugados y usos de los mismos. MX2019010804A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762471886P 2017-03-15 2017-03-15
US201762573630P 2017-10-17 2017-10-17
US201862622780P 2018-01-26 2018-01-26
PCT/US2018/022510 WO2018170179A1 (en) 2017-03-15 2018-03-14 Benzazepine compounds, conjugates, and uses thereof

Publications (1)

Publication Number Publication Date
MX2019010804A true MX2019010804A (es) 2020-01-23

Family

ID=63523998

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010804A MX2019010804A (es) 2017-03-15 2018-03-14 Compuestos de benzazepina, conjugados y usos de los mismos.

Country Status (16)

Country Link
US (5) US10239862B2 (es)
EP (2) EP3949969A3 (es)
JP (1) JP2020514419A (es)
KR (1) KR20200031560A (es)
CN (1) CN110612104A (es)
AU (1) AU2018236272B2 (es)
BR (1) BR112019019116A2 (es)
CA (1) CA3055652A1 (es)
DK (1) DK3595668T3 (es)
ES (1) ES2894731T3 (es)
HU (1) HUE056427T2 (es)
IL (1) IL269283B2 (es)
MX (1) MX2019010804A (es)
PT (1) PT3595668T (es)
SG (5) SG10202110184XA (es)
WO (1) WO2018170179A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7022702B2 (ja) * 2016-05-23 2022-02-18 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 第二級アミド基を有するベンズアゼピンジカルボキサミド化合物
AU2017292934B9 (en) 2016-07-07 2024-08-29 Bolt Biotherapeutics, Inc. Antibody adjuvant conjugates
HUE056427T2 (hu) 2017-03-15 2022-02-28 Silverback Therapeutics Inc Benzazepin vegyületek, konjugátumok és alkalmazásaik
JP2021506827A (ja) * 2017-12-15 2021-02-22 シルバーバック セラピューティックス インコーポレイテッド 肝炎の治療用の抗体コンストラクト−薬物コンジュゲート
CN112153988A (zh) 2018-05-17 2020-12-29 博尔特生物治疗药物有限公司 免疫缀合物
KR20210025522A (ko) 2018-06-25 2021-03-09 유니버시티 오브 워싱톤 강력하고 선택적인 인터루킨 모방체의 드 노보 디자인
KR20210081339A (ko) * 2018-09-12 2021-07-01 실버백 테라퓨틱스, 인크. 치환된 벤즈아제핀 화합물, 접합체, 및 이의 용도
SG11202101980VA (en) * 2018-09-12 2021-03-30 Silverback Therapeutics Inc Methods and composition for the treatment of disease with immune stimulatory conjugates
WO2020056194A1 (en) * 2018-09-12 2020-03-19 Silverback Therapeutics, Inc. Benzazepine compounds, conjugates, and uses thereof
EP3883956A1 (en) 2018-11-20 2021-09-29 University of Washington Split interleukin mimetics and their use
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
EP3966248A4 (en) * 2019-05-08 2023-04-12 Memorial Sloan Kettering Cancer Center HUMAN ANTIBODIES TO FEL MUCIN-16 AND THEIR METHODS OF USE
US20200390899A1 (en) * 2019-06-13 2020-12-17 Bolt Biotherapeutics, Inc. Aminobenzazepine compounds, immunoconjugates, and uses thereof
US20220315537A1 (en) * 2019-06-13 2022-10-06 Bolt Biotherapeutics, Inc. Macromolecule-supported aminobenzazepine compounds
WO2020257407A1 (en) 2019-06-19 2020-12-24 Silverback Therapeutics, Inc. Anti-mesothelin antibodies and immunoconjugates thereof
WO2021030665A1 (en) 2019-08-15 2021-02-18 Silverback Therapeutics, Inc. Formulations of benzazepine conjugates and uses thereof
EP4038053A1 (en) * 2019-09-30 2022-08-10 Bolt Biotherapeutics, Inc. Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
CA3151322A1 (en) * 2019-10-01 2021-04-08 Silverback Therapeutics, Inc. Combination therapy with immune stimulatory conjugates
WO2021072330A1 (en) 2019-10-09 2021-04-15 Silverback Therapeutics, Inc. Galnac-tgfbr1 inhibitor conjugates for the treatment of liver diseases
WO2021072203A1 (en) 2019-10-09 2021-04-15 Silverback Therapeutics, Inc. Tgfbetar1 inhibitor-asgr antibody conjugates and uses thereof
US11554999B2 (en) 2019-11-15 2023-01-17 Goodrich Corporation Inflation systems for evacuation slides and life rafts
WO2021168274A1 (en) 2020-02-21 2021-08-26 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
EP4121449A2 (en) 2020-03-16 2023-01-25 Neoleukin Therapeutics, Inc. Interleukin-2 receptor beta (il-2rb) binding polypeptides
EP4132964A2 (en) 2020-04-07 2023-02-15 Neoleukin Therapeutics, Inc. De novo protein decoys of angiotensin-converting enzyme 2 (ace2)
KR20230047361A (ko) 2020-07-01 2023-04-07 아르스 파마슈티컬스 인크. 항-asgr1 항체 접합체 및 이의 용도
CN116507639A (zh) * 2020-08-04 2023-07-28 埃克塞里艾克西斯公司 Cd47结合剂及其用途
EP4192884A4 (en) * 2020-08-04 2025-04-09 Exelixis, Inc. PD-L1-BINDING AGENTS AND USES THEREOF
WO2022036101A1 (en) * 2020-08-13 2022-02-17 Bolt Biotherapeutics, Inc. Pyrazoloazepine immunoconjugates, and uses thereof
US20220195066A1 (en) * 2020-12-11 2022-06-23 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
JP2024508976A (ja) * 2021-03-08 2024-02-28 ジーンクアンタム ヘルスケア （スーチョウ） シーオー．， エルティーディー． 抗体－免疫アゴニストコンジュゲート及びその使用
AU2022253902A1 (en) 2021-04-10 2023-11-02 Genmab A/S Folr1 binding agents, conjugates thereof and methods of using the same
JP7742892B2 (ja) 2021-04-23 2025-09-22 ジェンマブ エー／エス 抗ｃｄ７０抗体、そのコンジュゲートおよびこれを使用する方法
EP4342884A4 (en) * 2021-05-19 2025-10-29 Shanghai De Novo Pharmatech Co Ltd Compound containing nitrogen, conjugate containing said compound, and associated use
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
WO2023044318A2 (en) 2021-09-15 2023-03-23 Neoleukin Therapeutics, Inc. Interleukin-2 receptor βeta (il-2rβ) binding polypeptides
WO2023154318A1 (en) * 2022-02-09 2023-08-17 Bolt Biotherapeutics, Inc. Anti-tr0p2, aminobenzazepine immunoconjugates, and uses thereof
WO2024067841A1 (zh) * 2022-09-30 2024-04-04 上海迪诺医药科技有限公司 苯并氮杂卓衍生物、含其的偶联物及其应用
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
AR133955A1 (es) 2023-09-26 2025-11-19 Profoundbio Us Co Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物
WO2025149661A1 (en) 2024-01-10 2025-07-17 Genmab A/S Slitrk6 binding agents, conjugates thereof and methods of using the same
US20250381289A1 (en) 2024-02-29 2025-12-18 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
WO2025194123A1 (en) * 2024-03-15 2025-09-18 Aarvik Therapeutics, Inc. Muc16/napi-2b antibodies and methods of use

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
ATE372966T1 (de) 1994-03-25 2007-09-15 Isotechnika Inc Verbesserung der effektivität von arzneimitteln duren deuterierung
US6130217A (en) * 1995-09-20 2000-10-10 Pfizer Inc Compounds enhancing antitumor activity of other cytotoxic agents
PT825186E (pt) 1996-08-16 2002-08-30 Pfizer Derivados de 2-aminobenzazepina e sua utilizacao para o tratamento da imunossupressao
US20040141983A1 (en) 1999-03-15 2004-07-22 Protein Design Labs, Inc. Compositions against cancer antigen LIV-1 and uses thereof
US6953787B2 (en) * 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
US7585326B2 (en) 2004-08-06 2009-09-08 Spinalmotion, Inc. Methods and apparatus for intervertebral disc prosthesis insertion
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
TW201402124A (zh) * 2005-08-19 2014-01-16 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
US8691809B2 (en) 2009-08-18 2014-04-08 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
CN102781933B (zh) 2009-08-18 2016-01-20 文蒂雷克斯药品公司 作为toll样受体调节剂的取代的苯并氮杂*
PT2552959T (pt) 2010-03-26 2017-04-21 Memorial Sloan Kettering Cancer Center Anticorpos para muc16 e métodos de utilização dos mesmos
SI3461847T1 (sl) 2010-12-06 2021-03-31 Seagen Inc. Humanizirana protitelesa proti LIV-1 in njihova uporaba pri zdravljenju raka
BR112013017947A2 (pt) 2011-01-12 2018-12-18 Array Biopharma Inc benzoazepinas substituídas como moduladores de receptor toll-like
MX346387B (es) 2011-01-12 2017-03-02 Ventirx Pharmaceuticals Inc Benzoazepinas sustituidas como moduladores de receptores tipo toll.
WO2013033345A1 (en) * 2011-08-30 2013-03-07 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
WO2015110935A1 (en) * 2014-01-27 2015-07-30 Pfizer Inc. Bifunctional cytotoxic agents
HRP20192254T1 (hr) 2014-04-25 2020-03-06 Pierre Fabre Medicament Konjugat antitijela i lijeka i njegova upotreba u liječenju karcinoma
CN105233291A (zh) 2014-07-09 2016-01-13 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
KR20170118700A (ko) 2014-12-16 2017-10-25 셀진 코포레이션 (1e,4e)-2-아미노-n,n-디프로필-8-(4-(피롤리딘-1-카보닐)페닐)-3h-벤조[b]아제핀-4-카복사미드를 포함하는 고체형, 이의 조성물, 및 이의 용도
WO2016096778A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Benzazepine sulfonamide compounds
JP6676058B2 (ja) * 2015-01-14 2020-04-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヘテロアリーレン架橋したベンゾジアゼピン二量体、そのコンジュゲート、ならびに製造および使用方法
MX364223B (es) 2015-03-06 2019-04-16 Hoffmann La Roche Compuestos de dicarboxamida de benzazepinas.
US9943416B2 (en) 2015-03-10 2018-04-17 Simplify Medical Pty Limited Intervertebral spacer that dynamically promotes bone growth
EP3442934A4 (en) 2016-04-13 2019-12-11 Siluria Technologies, Inc. OXIDATIVE COUPLING OF METHANE FOR THE PRODUCTION OF OLEFIN
PL3453707T3 (pl) 2016-05-06 2022-06-13 Shanghai De Novo Pharmatech Co., Ltd. Pochodna benzazepiny, sposób wytwarzania, kompozycja farmaceutyczna i jej zastosowanie
EP3464245B1 (en) * 2016-05-23 2020-10-14 H. Hoffnabb-La Roche Ag Benzazepine dicarboxamide compounds with tertiary amide function
JP7022702B2 (ja) * 2016-05-23 2022-02-18 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 第二級アミド基を有するベンズアゼピンジカルボキサミド化合物
WO2017216054A1 (en) 2016-06-12 2017-12-21 F. Hoffmann-La Roche Ag Dihydropyrimidinyl benzazepine carboxamide compounds
US20190336615A1 (en) * 2017-01-27 2019-11-07 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
EP3576782A4 (en) 2017-02-02 2020-12-30 Silverback Therapeutics, Inc. COMPOSITIONS OF RECOMBINATION PRODUCT-PEPTIDE AND THEIR METHODS OF USE
HUE056427T2 (hu) 2017-03-15 2022-02-28 Silverback Therapeutics Inc Benzazepin vegyületek, konjugátumok és alkalmazásaik

Also Published As

Publication number Publication date
US10239862B2 (en) 2019-03-26
US10442790B2 (en) 2019-10-15
ES2894731T3 (es) 2022-02-15
RU2019132260A (ru) 2021-04-15
BR112019019116A2 (pt) 2020-05-05
CN110612104A (zh) 2019-12-24
SG10202110182PA (en) 2021-10-28
DK3595668T3 (da) 2021-10-18
HUE056427T2 (hu) 2022-02-28
US10519131B2 (en) 2019-12-31
US20190169164A1 (en) 2019-06-06
SG10202110183VA (en) 2021-10-28
EP3949969A3 (en) 2022-02-16
IL269283A (en) 2019-11-28
WO2018170179A1 (en) 2018-09-20
SG10202110184XA (en) 2021-10-28
AU2018236272A1 (en) 2019-10-17
KR20200031560A (ko) 2020-03-24
US20180258048A1 (en) 2018-09-13
EP3595668A4 (en) 2020-04-01
AU2018236272B2 (en) 2022-03-31
CA3055652A1 (en) 2018-09-20
EP3949969A2 (en) 2022-02-09
US10428045B2 (en) 2019-10-01
SG11201908131RA (en) 2019-10-30
IL269283B2 (en) 2023-04-01
EP3595668A1 (en) 2020-01-22
IL269283B (en) 2022-12-01
EP3595668B1 (en) 2021-07-21
RU2019132260A3 (es) 2021-12-07
US20190062306A1 (en) 2019-02-28
US20200031798A1 (en) 2020-01-30
SG10202110181RA (en) 2021-10-28
JP2020514419A (ja) 2020-05-21
PT3595668T (pt) 2021-10-21
US20190169165A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
MX2019010804A (es) Compuestos de benzazepina, conjugados y usos de los mismos.
MX2020012679A (es) Compuestos de amino-pirazincarboxamida, conjugados, y usos de los mismos.
ZA201907233B (en) Conjugation of a cytotoxic drug with bis-linkage
NZ752526A (en) Pyrrolobenzodiazepine conjugates
PH12020500396A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
PH12019501663A1 (en) Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
MX2024008464A (es) Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente.
MY206244A (en) Anti-muc1 antibody-drug conjugate
MX2021010550A (es) Conjugados de anticuerpo-farmaco hidrofilicos.
WO2020056198A3 (en) Substituted benzazepine compounds, conjugates, and uses thereof
GEAP202214922A (en) Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof
MY178160A (en) Anti-egfrviii antibodies and uses thereof
NZ748314A (en) Anti-cmet antibody drug conjugates and methods for their use
WO2017031458A3 (en) Anti-dll3 antibody drug conjugates and methods of use
MX2023013995A (es) Conjugados de anticuerpo y antraciclina.
NZ741261A (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
MX2021008334A (es) Ligadores que modulan la estabilidad para usar con conjugados anticuerpo-farmaco.
MY202233A (en) Compositions of phosphorylated tau peptides and uses thereof
NZ725480A (en) Anti-ptk7 antibody-drug conjugates
NZ756730A (en) Combination therapy with an anti-axl antibody-drug conjugate
MX2016016515A (es) Derivados de auristatina y conjugados de los mismos.
MX2016007865A (es) Peptidos citotoxicos y conjugados de los mismos.
MX2020006010A (es) Conjugados de anticuerpo anti-cd22-maitansina, combinaciones y metodos de uso de los mismos.
EP3566750A3 (en) Conjugates comprising cell-binding agents and cytotoxic agents
MX2021015533A (es) Anticuerpos anti-mesotelina e inmunoconjugados de los mismos.